Last night, advocates with the American Cancer Society Cancer Action Network (ACS CAN), NJ Citizen Action and the NJ Black Empowerment Coalition convened a roundtable discussion on the impacts of the budget reconciliation bill in front of Congress on Americans’ access to Medicaid and Marketplace coverage.
Earlier this week, the New Jersey State Assembly voted to advance a bill that seeks to create more stability for patients. The proposal (Assembly Bill 5217) would curb an unfair insurance practice that makes critical medication more expensive and access unpredictable. With its passage in committee, advocates with the American Cancer Society Cancer Action Network (ACS CAN) are hopeful that the Senate Budget & Appropriations Committee see the bill’s momentum as a call to action to take the final steps to pass and enact the necessary reforms.
Yesterday, both chambers in the New Jersey State Legislature passed legislation (Assembly Bill 4163 / Senate Bill 3098) to increase access to biomarker testing, which can help determine the best treatment plan for each patient. The bill will now go to Governor Murphy’s desk, providing him the opportunity to ensure coverage of this essential testing for more New Jerseyans. The American Cancer Society Cancer Action Network (ACS CAN) is leading the efforts on this significant policy change to ensure more patients can get the testing needed to access precision medicine.
Earlier this week, New Jersey Governor Phil Murphy released his proposed budget for 2025. In response, the American Cancer Society Cancer Action Network (ACS CAN) New Jersey Government Relations Director Quinton Law issued the following statement, highlighting how Governor Murphy can amplify his intended impact of improving public health and addressing the deficit by increasing the cigarette tax by $1 per pack.
Last month, the American Cancer Society (ACS) released its annual report on cancer facts and trends, which found that, between 2017 and 2021, New Jersey had the highest incidence of pancreatic cancer behind D.C. It also found that progress is lagging for pancreatic cancer with incidence and mortality both increasing, and the 5-year survival for 9 out of 10 people diagnosed with tumors in the exocrine pancreas sitting at just 8%. Despite the concerning data, local pancreatic cancer survivor Nick Pifani is optimistic and views a path forward, in part through expanded access to biomarker testing. He is calling on leaders to help to improve access to biomarker testing when Assembly Bill 4163 / Senate Bill 3098 come under consideration.
The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) New Jersey Government Relations Director Quinton Law:
“As anybody touched by the disease can tell you, cancer demands a high price. Physically, emotionally and financially, it is a draining disease where the costs can—very quickly—feel insurmountable. This is the case for patients across the cancer continuum. New Jerseyans are looking for state leaders to intervene and prevent the costs of care from trending upward and potentially trapping them in a lifetime of medical debt. Cancer patients and survivors throughout the state were heartened to hear Governor Murphy isolate affordability as a priority in his State of the State address. In the coming year, ACS CAN urges lawmakers to focus their efforts on three areas to alleviate the financial burden of disease, starting with preventing illness for a group of New Jerseyans at heightened risk of cancer: Atlantic City casino workers.
Two years after Ocean City local Jeanmarie Mason’s breast cancer returned and spread to her bones, her daughter Julie Groob also experienced a recurrence of her cervical cancer, bringing the two closer together than ever and uniting them in the fight against cancer. As volunteers with the American Cancer Society Cancer Action Network (ACS CAN), Jeanmarie and Julie were among key voices in securing a medical debt relief victory in 2024. The pair are approaching the legislative session in 2025 eager to share their stories and advance critical proposals to limit the burden of disease across the cancer continuum.
This week, New Jersey lawmakers approved legislation to improve access to biomarker testing with a unanimous vote by the Assembly Appropriations Committee. Assembly Bill 4163 now awaits a vote on the Assembly floor. The Senate advanced identical legislation (Senate Bill 3098) in the Senate Commerce Committee last week, which now awaits further consideration by the Senate Budget & Appropriations Committee. Advocates with the New Jersey Biomarker Testing Coalition are hopeful that the bills will receive the necessary support to secure swift passage in the new year.
Earlier today, Senate Bill 3098 was unanimously voted out of the Senate Commerce Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate Budget & Appropriations Committee for further consideration. In October, the Assembly Financial Institutions & Insurance Committee approved identical legislation (Assembly Bill 4163), which now awaits a hearing in the Assembly Appropriations Committee.
Key public health, patient and provider groups have come out in support of improving access to biomarker testing in New Jersey, urging lawmakers to advance and pass Assembly Bill 4163 / Senate Bill 3098 this legislative session. This fall, a broad coalition of over 30 organizations, medical leaders and patient advocates wrote to members of the Assembly Financial Institutions & Insurance (AFI) Committee to vote in favor of A4163, which they did—unanimously—several weeks ago. Now, the New Jersey Biomarker Coalition is looking to the Assembly Appropriations and Senate Commerce Committees to take up this bill and follow the lead of their AFI member colleagues.